New Product Launch: The “Buffer Solution”—a Revolutionary Tool for Carbapenemase Phenotype Detection
Release Date:
2020-06-02
Currently, carbapenem‑resistant Enterobacteriaceae (CRE) are rapidly spreading and becoming endemic in healthcare settings, posing a major global public health challenge. Data from the CHINET surveillance network indicate that the rate of carbapenem resistance among Klebsiella pneumoniae has been steadily increasing, reaching nearly 30% by 2018. Infections caused by CRE strains are often associated with high mortality; studies show that invasive infections—such as bloodstream infections—attributable to CRE can carry mortality rates as high as 40% to 50%...
1
The Necessity of Phenotypic Detection of Carbapenemases
1.1 Current Status of Carbapenem-Resistant Enterobacteriaceae (CRE) in China
Currently, carbapenem‑resistant Enterobacteriaceae (CRE) are rapidly spreading and becoming endemic in healthcare settings, posing a major global public health challenge. Data from the CHINET surveillance network indicate that the rate of carbapenem resistance among Klebsiella pneumoniae has been steadily increasing, approaching 30% by 2018. Infections caused by CRE strains are often associated with high mortality; studies show that invasive infections—such as bloodstream infections—attributable to CRE can carry mortality rates as high as 40% to 50%.
1.2 Clinical Significance of Carbapenemase Phenotypic Testing
Carbapenemases are a major class of β-lactamases capable of hydrolyzing carbapenem antibiotics and can be classified into Classes A, B, and D. Classes A and D are serine enzymes, while Class B comprises metalloenzymes. Among them, the KPC serine carbapenemase of Class A has emerged in recent years as the predominant resistance mechanism in Enterobacteriaceae; it is inhibited by novel enzyme inhibitors such as avibactam and relebactam. Clinically, ceftazidime–avibactam is frequently used to treat infections caused by KPC‑producing organisms. In addition, the NDM metalloenzyme of Class B exhibits weak hydrolytic activity against aztreonam and is not inhibited by standard β‑lactamase inhibitors; therefore, the combination of aztreonam with ceftazidime–avibactam represents an effective therapeutic strategy for infections due to NDM‑producing bacteria. Consequently, clinicians can select appropriate treatment regimens based on the classification of carbapenemases, thereby improving the management of carbapenem‑resistant Enterobacteriaceae (CRE).
1.3 Industry Attention
Starting in the fourth quarter of 2019, the CARSS network has mandated the submission of phenotypic and genotypic test results for carbapenemase‑producing Enterobacteriaceae (CRE) strains. Laboratories with the capacity are encouraged to respond promptly; initially, all institutions hosting provincial surveillance centers are required to report carbapenemase test results.
2
Common Methods for Detecting Carbapenemase in Clinical Practice
As demonstrated by the aforementioned carbapenemase detection methods, the enzyme inhibitor assay not only enables the typing of carbapenemases but also offers simple operation, easy-to-interpret results, and low cost, making it highly suitable for clinical use in phenotypic detection of carbapenemases.
Enzyme inhibitor method
01 Principle
Class A carbapenemases are inhibited by boronic acid compounds but not by EDTA; Class B enzymes are inhibited by EDTA but not by boronic acid compounds.
02 Operating Instructions
a. Spread 0.5 McFarland units of the test bacterial suspension onto an MH agar plate.
b. Place four imipenem disks, spaced 25 mm apart.
c. On three separate filter papers, dispense 10 µL of EDTA solution, 10 µL of APB solution, and 10 µL of a mixture containing both EDTA and APB solutions, respectively.
d. Read the results after incubating at 35℃ overnight.
03 Result Interpretation
If the diameter of the inhibition zone containing an enzyme inhibitor differs from that of the single‑agent test by ≥5 mm, the tested strain can be classified as producing a class A or class B carbapenemase.
3
Dil’s new buffer solution (carbapenemase)
Product specifications: APB 1 ml × 1, EDTA 1 ml × 1
Product Use: This buffer, in combination with carbapenem antibiotic discs (imipenem is recommended), is used for the typing of carbapenemases.
Product Advantages:
(1) Utilizes an enzyme inhibitor methodology; no solution preparation is required—simply open the cap and use.
(2) It can be used for carbapenemase typing; the assay is simple to perform, and the results are easy to interpret.
(3) Low consumption and low cost: a single carbapenemase phenotypic assay requires only about 40 μL of buffer, and one kit can support multiple assays.
(4) The reagents are stable, and the experimental results are excellent.
Related News
DL Biotech: Making infectious disease diagnosis faster and more accurate.
Are you ready to embark on a journey into the world of microbes?
DL Biotech WeChat Official Account
Tel: 0756-3391888
Zhuhai DL Biotech Co., Ltd.
Address: No. 59, Dingwan 10th Road, Jinwan District, Zhuhai City
Email: market@medicaldl.com
dl@medicaldl.com (for export business)
National After-Sales Customer Service Hotline: 400-9313-018
International Customer Service Hotline: +86 756 6292044
©2026 Zhuhai DL Biotech Co., Ltd.Website Development: China Enterprise Dynamics Zhuhai
SEO tags
Sorry, there is currently no content in this section.
You can view other sections.
Sorry, there is currently no content in the current column
You can check other sections
Business license
Business License